14 Nov 2023
18:00 -21:00
Times are shown in local time.
Open to: All
Cambridge Judge Business School
Trumpington St
Cambridge
Cambridgeshire
CB2 1AG
United Kingdom

Entrepreneurs are recognising that artificial intelligence (AI) is generating opportunities that place them at the forefront of innovation. As well as disrupting traditional industry sectors, these new technologies have the potential to solve some of society’s most challenging problems.
Across healthcare, AI is laying the groundwork for the discovery and application of better diagnostics and treatments, more efficient use of resources, and the delivery of a net zero health industry – perhaps even improving our environment and making us better or enhanced humans. In food, AI is facilitating personalised nutrition, optimising crop production, and enabling food transparency and better resource allocation. And in consumer markets, AI customer analytic tools are creating new business opportunities and levelling up markets as businesses use data to gain deeper customer insights. Any entrepreneur using AI in their start up can expect more innovative business models alongside quicker, more effective routes to market, even access to finance.
The flip side to these opportunities are the emerging concerns around AI being the last great innovation as it becomes smarter than us and what impact this could have on our society, together with practical concerns around data collection and its ethical use, fake realities and the erosion of our privacy – even the threat of body hacking.
How should entrepreneurs safely navigate these risks to create game changing new opportunities? Join us for a stimulating evening of discussion and hear from a panel of AI-pioneering experts who will talk us through these opportunities and risks. All followed by networking and drinks.
Dr Loubna Bouarfa is an accomplished machine learning scientist turned entrepreneur, recognized by Forbes as one of the Top 50 Women in Tech, and by MIT Technology Review.
As founder of OKRA.ai, a leading artificial intelligence company for life sciences, Dr Bouarfa supports the pharma industry in bringing the right drug to the right patient at speed. OKRA.ai, ranked 9th in Deloitte’s UK fastest-growing tech companies, recently joined forces with Envision Pharma Group, where Loubna leads the development of cutting-edge AI solutions in the life sciences industry, as the Head of AI and Innovative Platforms.
Loubna contributes as a thought leader within European institutions, supporting the European Commission and member states in the drafting of ethical guidelines for the future of artificial intelligence. She has also acted as adviser in the recent work UN has undertaken on AI, to create guidelines for the use and application of AI by SMEs in developing countries.
Saskia Pauly is Co-Founder and CEO of CrunchMate – the first AI-driven “Front Desk Concierge” on Instant Messaging. Firmly believing in technology democratisation as a cornerstone of global empowerment and democracy, Saskia strives to make responsible AI solutions available to businesses of all industries and sizes.
Prior to CrunchMate, she led the Data & AI Innovation Hub at Accenture in Germany and co-founded her own Data & AI Advisory Business in 2022. Saskia holds a French-German dual Master’s degree in Management from FAU Erlangen-Nürnberg and EM Strasbourg Business School. She is part of the Cohort 32 of the Accelerate Cambridge Program.
Anthony (Tony) Harris is an experienced business angel, entrepreneur, technologist, and thirty-year tech-industry veteran. After working in systems software and product management in the USA he co founded Software 2000/Software Imaging UK and the company’s OEM software revolutionised colour desktop inkjet and digital copier printing worldwide. After exiting in 2007 he completed an MA (Oxon), an MA(Res), and a PhD (Cantab).
Tony has an established track-record in technology start-ups, software development, intellectual property, revenue generation, and financial turnarounds. He is a non-executive director of various Cambridge companies, a member of Cambridge Angels, and sits on the board as treasurer. His areas of expertise include software development, building successful teams, financial turnarounds, corporate finance and taxation, audit oversight, income stream generation, international sales and marketing (OEM and retail), royalty and licensing models, and intellectual property licensing. To-date he has invested in nearly fifty start-ups of which several are in the AI space.
Richard’s mission is to empower brilliant scientists with the tools to redefine industries using engineered biology.
Richard is co-founder, CEO and Chair of BiologIC Technologies. BiologIC’s integrated bioprocessing platform is trusted by leading customers to enhance yields, process robustness and scalability of advanced biology products. The platform, enabled by novel biocomputer technology, enables new categories of machines to be built from fluidic processing chips designed like computer chips. Our vision is to help customers engineer biology to solve enormous challenges faced by humanity (feeding 9.8 billion people by 2050, mitigating climate change and reducing the threat of diseases) in an environmentally sustainable, economically accessible way.
In 7 valuable years as interim CEO, deputy CEO, CFO, COO and Company Secretary, Richard was instrumental in growing Horizon Discovery Group plc from an emerging private company of £3m revenue in 2012 to a recognised global leader in gene editing delivering revenue of £60m at a valuation of £350m. Richard delivered one of the most successful ever Life Science listings on AIM raising £68.6m in a heavily oversubscribed IPO at the top of its valuation range within 3 months, fundraisings in the UK and the US, four acquisitions and hostile bid defence.
Richard was previously Vice President, Finance at CSR plc, a dual listed FTSE 250 semiconductor company with $1bn of revenues, and a director in Deloitte’s life sciences practice. Richard is a qualified chartered accountant with a first class degree in biological sciences from Durham University.
This event has now reached capacity, but you can register for streaming: